Journal article · 2026 · Open access

An ulcerative colitis taxonomy defined by individual patient-reported response trajectories

Stefan Schreiber, Vijay Yajnik, Cenfu Wei, Maria D. Paraskevopoulou, Saman Farahmand, Jie Cheng, Katherine H. Simpson, Zitong Lin, Christian Agboton, Pratik Panchal, Banishree Saha, Ninfa M. Candela and 11 more

Nature Medicine · Published 9 November 2026 · DOI 10.1038/s41591-026-04741-8

Open PDFView at the publisherCite this paper

In brief

“An ulcerative colitis taxonomy defined by individual patient-reported response trajectories” is a 2026 journal article by Stefan Schreiber and 22 co-authors, published in Nature Medicine. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Nature Medicine.

Citations
0
References
100
Authors
23

Abstract

A barrier to precision medicine for ulcerative colitis (UC) is the inability to predict and mechanistically explain treatment responses. Using patient-reported outcomes (PROs) from a phase 3b comparative trial of 768 participants, we identified four distinct patient response-trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor). Validation in a second phase 3 trial of 576 participants linked PRO-defined vedolizumab trajectories to long-term disease complications. Bulk, single cell, and spatial transcriptomics and proteomics identified vascular inflammation as associated with vedolizumab nonresponse through interactions between SPP1 + macrophages and endothelial cells. In two separate real-world cohorts of 4,981 and 3,854 patients with UC, concomitant use of renin–angiotensin system inhibitors (modulators of vascular inflammation) was associated with reduced long-term complications for vedolizumab but not anticytokine therapies. These findings define a response-trajectory-based taxonomy that requires prospective validation for clinical utility and applications for selecting vedolizumab combination therapy in UC.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Schreiber, S., Yajnik, V., Wei, C., Paraskevopoulou, M. D., Farahmand, S., Cheng, J., Simpson, K. H., Lin, Z., Agboton, C., Panchal, P., Saha, B., Candela, N. M., Brown, J., Peshek, I. M., Chavez, F., Rosas, L., Robinson, A., Kochhar, G. S., Desai, A., . . . Dulai, P. S. (2026). An ulcerative colitis taxonomy defined by individual patient-reported response trajectories. Nature Medicine. https://doi.org/10.1038/s41591-026-04741-8

MLA 9

Schreiber, Stefan, et al. “An ulcerative colitis taxonomy defined by individual patient-reported response trajectories.” Nature Medicine, 2026. https://doi.org/10.1038/s41591-026-04741-8.

Chicago

Schreiber, Stefan, Vijay Yajnik, Cenfu Wei, Maria D. Paraskevopoulou, Saman Farahmand, Jie Cheng, Katherine H. Simpson, et al. 2026. “An ulcerative colitis taxonomy defined by individual patient-reported response trajectories.” Nature Medicine. https://doi.org/10.1038/s41591-026-04741-8.

Harvard

Schreiber, S. et al. (2026) ‘An ulcerative colitis taxonomy defined by individual patient-reported response trajectories’, Nature Medicine. doi:10.1038/s41591-026-04741-8.

IEEE

S. Schreiber et al., “An ulcerative colitis taxonomy defined by individual patient-reported response trajectories,” Nature Medicine, 2026, doi: 10.1038/s41591-026-04741-8.

BibTeX

@article{schreiber2026ulcerative,
  title     = {{An ulcerative colitis taxonomy defined by individual patient-reported response trajectories}},
  author    = {Schreiber, Stefan and Yajnik, Vijay and Wei, Cenfu and Paraskevopoulou, Maria D. and Farahmand, Saman and Cheng, Jie and Simpson, Katherine H. and Lin, Zitong and Agboton, Christian and Panchal, Pratik and Saha, Banishree and Candela, Ninfa M. and Brown, Joshua and Peshek, Isabella Marie and Chavez, Frida and Rosas, Libeth and Robinson, Alan and Kochhar, Gursimran Singh and Desai, Aakash and Kimmig, Franziska and Rosenstiel, Philip C and Thakker, Paresh and Dulai, Parambir Singh},
  journal   = {Nature Medicine},
  year      = {2026},
  doi       = {10.1038/s41591-026-04741-8},
  url       = {https://doi.org/10.1038/s41591-026-04741-8}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease

  • ulcerative colitis
  • vedolizumab
  • adalimumab
  • patient-reported outcomes
  • treatment response trajectories
  • precision medicine
  • vascular inflammation
  • endothelial cells

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Schreiber, S., Yajnik, V., Wei, C., Paraskevopoulou, M. D., Farahmand, S., Cheng, J., Simpson, K. H., Lin, Z., Agboton, C., Panchal, P., Saha, B., Candela, N. M., Brown, J., Peshek, I. M., Chavez, F., Rosas, L., Robinson, A., Kochhar, G. S., Desai, A., . . . Dulai, P. S. (2026). An ulcerative colitis taxonomy defined by individual patient-reported response trajectories. Nature Medicine. https://doi.org/10.1038/s41591-026-04741-8

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Stefan Schreiber, Vijay Yajnik, Cenfu Wei, Maria D. Paraskevopoulou, Saman Farahmand, Jie Cheng, Katherine H. Simpson, Zitong Lin, Christian Agboton, Pratik Panchal, Banishree Saha, Ninfa M. Candela and 11 more.

What is the DOI of this paper?

10.1038/s41591-026-04741-8, permanently at https://doi.org/10.1038/s41591-026-04741-8. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.